Deal combines new lung cancer agent with targeted inhaled delivery
UK inhaled therapies developer Vectura Group (LSE: VEC) has signed an exclusive global agreement for the application of its smart nebulizer technology with US immunotherapy specialist Dynavax Technologie (Nasdaq: DVAX) to deliver a lung cancer agent.
Vectura’s AKITA smart nebulizer will be used by Dynavax to deliver DV281, a novel toll-like receptor 9 (TLR9) agonist designed specifically for local delivery to primary lung tumors and lung metastases in order to generate an anti-tumor immune response.
Vectura’s nebulization technology combines optimizing patient’s inhalation technique with the effective control of the flow rate and volume of the drug being delivered, the company says. This approach maximizes the efficiency of the nebulization and enables consistent targeted drug deposition.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze